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Pulling in more fat
In obesity, skeletal muscle accumulates triglyceride. Recent work from Hulver and colleagues (2005) in the October issue
of Cell Metabolism implicates stearoyl-CoA desaturase as part of the underlying molecular mechanism.
Pascual, G., Fong, A.L., Ogawa, S., Gamliel, A., DOI 10.1016/j.cmet.2005.10.004Obesity and the related comorbid meta-
bolic condition of type 2 diabetes are
characterized by an increased accumu-
lation of triglyceride in skeletal muscle.
Considered in absolute terms relative to
the expanded adipose tissue mass that
defines obesity, the increase in muscle
triglyceride content is seemingly trivial.
Yet, it has become increasingly clear
that augmentation of muscle triglyceride
content can act as a potent “metabolic
signal” initiating or aggravating insulin
resistance of skeletal muscle in obesity
and type 2 DM (Pan et al., 1997). A nota-
ble exception is the observation that
skeletal muscle of highly trained, lean in-
dividuals also has a heightened content
of triglyceride but with no associated in-
sulin resistance.
The mechanisms linking the accumu-
lation of muscle triglyceride with insulin
resistance are not fully understood, and
several theories have been advanced.
One is that, in muscle of the obese, other
lipid moieties that accumulate along with
triglycerides may more directly mediate
insulin resistance. Another concept put
forward is that in the setting of increased
muscle triglyceride in obesity, an internal
milieu of inflammatory adaptations within
myocytes impairs insulin signaling and
induces insulin resistance. Recent work
published in the October issue of Cell
Metabolism (Hulver et al., 2005) has ad-
dressed the mechanisms underlying tri-
glyceride accumulation in obesity. These
findings suggest that triglyceride syn-
thesis within myocytes exerts a “pull” on
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iCELL METABOLISM : NOVEMBER 2005atty acids. Before addressing their find-
ngs in detail, it is important to consider
he physiological significance of the
tores of triglyceride and glycogen in
keletal muscle.
When glycogen content in skeletal
uscle is replete, this depot accounts
or nearly three-quarters of the total gly-
ogen stored in humans, with most of
he remainder contained in liver. Thus,
uantitatively muscle contains a large
roportion of systemic glycogen, and in
physiological context, it is well estab-
ished that glycogen content in muscle
xerts a strong influence on muscular
nd, consequently, systemic insulin sen-
itivity. Depletion of glycogen, such as
ith sustained, moderate, or higher-
ntensity physical activity, is followed by
n interval of heightened glucose uptake
y muscle and accelerated rates of gly-
ogen synthesis, which persist until gly-
ogen stores are replete. The opposite
hysiological response, that of dimin-
shed insulin sensitivity for glucose trans-
ort and stimulation of glycogen synthe-
is, occurs if the pool of glycogen within
uscle is filled or even modestly in-
reased. Thus, the robust cellular mecha-
isms that act to regulate muscle glyco-
en content do so with considerable
nfluence upon pathways which deter-
ine insulin sensitivity of skeletal mus-
le. Metabolic investigations over the
ast decade have begun to gather evi-
ence that the set of processes that
erve to link muscle content of triglycer-
de to the insulin sensitivity of this tissue
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rs only partially analogous to that ob-
erved for glycogen.
In addition to storing glucose in gran-
les of glycogen, skeletal muscle stores
riglyceride in lipid droplets. However,
ne key difference is that while muscle
lycogen represents a large proportion
f systemic glycogen, muscle content of
riglyceride constitutes only a minute
raction of its systemic reservoir, the
verwhelming proportion is contained in
dipocytes. However, as with skeletal
uscle glycogen, muscle triglyceride
xerts a strong metabolic signal impact-
ng upon insulin sensitivity of this tissue.
n lean, physically active individuals, the
mall reservoir of energy stored as tri-
lyceride in skeletal muscle is contained
ithin lipid droplets typically positioned
ear mitochondria (Hoppeler et al., 1985).
his lipid reserve is mobilized during
hysical activity, but unlike with glycogen,
hich is utilized during higher-intensity
xercise, muscle triglyceride is preferen-
ially utilized during sustained low- to
oderate-intensity exercise. Depletion
f muscle triglyceride following pro-
onged physical activity is followed by
n interval of accelerated efficiency in
riglyceride clearance from plasma, as
uscle triglyceride is replenished, a
esponse that seems analogous to gly-
ogen repletion following its depletion
uring physical activity. Repletion of gly-
ogen in muscle evokes mechanisms to
revent exaggerated accumulation, and
n obesity and other disorders of insulin
esistance there does not appear to be275
P R E V I E W San absolute increase in glycogen content
in muscle. An analogous process plac-
ing an upper limit on muscle triglyceride
content does not appear to be as robust
as is the case with glycogen, and as
noted above, there is elevated muscle tri-
glyceride content in obesity.
What are the mechanisms that drive
the elevated triglyceride content of skel-
etal muscle in obesity? Most prior studies
have pointed to the importance of “push”
toward fat storage that occurs as a con-
sequence of impaired capacity for fatty
acid oxidation. To briefly review the
“push” side of this equation, physiologi-
cal studies of skeletal muscle in obesity
have revealed a diminished reliance upon
fat oxidation during fasting conditions
when fat oxidation is ordinarily predomi-
nant (Hulver et al., 2003; Kelley et al.,
1999). Biochemical assessments have re-
vealed decreased enzymatic activities
within various aspects of the pathways
of fatty acid catabolism and oxidation
(Kelley et al., 2002; Simoneau et al.,
1999). Notably, skeletal muscle in obe-
sity characteristically has diminished ox-
idative enzyme activity and reduced ac-
tivity of the electron transport chain.
These relatively modest reductions would
not be severe enough to fully account
for impaired fat oxidation. Additional
inhibitory control may be exerted by
malonyl CoA, which allosterically inhibits
carnitine palmitoyl transferase I (Ras-
mussen et al., 2002; Ruderman et al.,
1999). CPT I is regarded as rate limiting
for entry of long chain acylCoA into the
mitochondrial matrix. Rates of fatty acid
uptake into skeletal muscle do not ap-
pear to be diminished in obesity and in
fact may be increased, related both to
higher circulating levels of plasma FFA
and to altered expression and activity of
fatty acid transport proteins (Campbell
et al., 2004). This line of investigation
has led to the concept that the accumu-
lation of triglyceride in muscle in obesity
and type 2 diabetes stems from normal
or increased rates of fatty acid influx in
the face of a decreased capacity for
fatty acid oxidation, thus partitioning or
pushing the net surplus of fatty acid to-
ward esterification as tissue triglyceride.
a
i
i
a
T
f
t
c
l
M
a
g
E
f
I
3
w
i
m
a
c
e
T
t
a
a
c
w
o
a
t
e
l
o
o
w
c
o
H
s
c
e
p
f
c
o
s
f
l
t
a
l
c276The elegant studies reported by Hulver
nd colleagues (2005) introduce the new
dea that additional mechanisms operat-
ng in skeletal muscle may pull fatty
cids toward esterification in obesity.
his work has revealed an important role
or stearoyl-CoA desaturase-1 (SCD-1),
he enzyme that converts saturated long
hain fatty acids to monounsaturated
ong chain fatty acids (Ntambi, 1995).
onounsaturated long chain fatty acids
re more readily incorporated into tri-
lyceride than are saturated fatty acids.
xamining muscle biopsy samples taken
rom women with severe obesity (class
II; BMI > 40 kg/m2) by gene array, a
-fold increase in expression of SCD-1
as observed compared to expression
n muscle samples obtained from nor-
al-weight women. Among the broad
rray of gene products examined in this
omparison, the difference for SCD-1
xpression was the most pronounced.
he investigators then used muscle cul-
ure systems to further examine SCD-1
ctivity and to manipulate its activity and
ssess the effects on muscle trigly-
eride. Myocytes cultured from obese
omen retained heightened expression
f SCD-1 in primary myocyte cultures,
nd tracer studies indicated retention of
he physiological phenotype of height-
ned partitioning into esterification and
ess toward oxidation. Overexpression
f SCD-1 in myotubes cultured from bi-
psy samples taken from normal-weight
omen induced this phenotype of in-
reased esterification and decreased fat
xidation. Taken together, the studies by
ulver and colleagues reveal that a les-
ened capacity for fat oxidation may be
oupled with an enhanced capacity for
sterification; acting in concert, these
ush and pull an increased proportion of
atty acid flux toward the abnormal ac-
umulation of muscle triglyceride in
besity and act to aggravate insulin re-
istance in this tissue that is important
or overall metabolic health.
There is much that remains to be
earned concerning the relative impor-
ance of altered SCD-1 expression and
ctivity in obesity. Interventions of weight
oss and physical activity can alter mus-
le triglyceride and improve insulin sen-
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Ditivity. Physical activity increases mito-
hondrial activity, but whether SCD-1
xpression and activity is influenced by
hese interventions and the crosstalk
ith other aspects of fatty acid metabo-
ism, specifically in the regulation of fatty
cid transport proteins and within the
athway of catabolism and oxidation of
atty acids, still remains to be more
learly delineated.
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